And here is your accompanying editorial: Leveraging Single-Cell Profiling in Early-Phase Trials to Guide Rational Therapy Development url: academic.oup.com/neuro-oncolo...

Leveraging Single-Cell Profiling in Early-Phase Trials to Guide Rational Therapy Development

Julia Louw, Jodie Jepson, Anna M Corcoran, Mustafa Khasraw; Leveraging Single-Cell Profiling in Early-Phase Trials to Guide Rational Therapy Development, N

academic.oup.com

Shwetal Mehta@shwetalm.bsky.social · 12mo ago

Very excited to have this collaborative work on evaluating PK/PD and single-cell responses for Ribociclib+Everolimus in #rGBM published. It was such a great experience working with @kevin-johnson.bsky.social and @roelverhaak.bsky.social. @ivycenter.bsky.social @anchitien.bsky.social

So excited to share @ivycenter.bsky.social’s publication on early phase clinical trial evaluating safety, feasibility and biological readouts of 5-ALA sonodynamic therapy (SDT) in recurrent high grade glioma patients. www.science.org/doi/10.1126/... @nadersanai.bsky.social @anchitien.bsky.social

An early clinical trial of 5-ALA sonodynamic therapy in recurrent high-grade glioma

An early clinical study demonstrates feasibility of noninvasive 5-ALA sonodynamic treatment in nine patients with recurrent high-grade glioma.

science.org

Very excited to have this collaborative work on evaluating PK/PD and single-cell responses for Ribociclib+Everolimus in #rGBM published. It was such a great experience working with @kevin-johnson.bsky.social and @roelverhaak.bsky.social. @ivycenter.bsky.social @anchitien.bsky.social

Roel Verhaak@roelverhaak.bsky.social · 12mo ago

Delighted to share this new collaborative paper with the Ivy BTC where we performed deep characterization of glioma patients enrolled on a CDK4/6i Phase 0 trial academic.oup.com/neuro-oncolo... with @kevin-johnson.bsky.social @shwetalm.bsky.social @nadersanai.bsky.social

Our PK-triggered Phase 0 hybrid trials require extensive assay development and validation. Today Dr. Karapetyan is presenting two posters from @ivycenter.bsky.social on PK assay validation for EGFR inhibitor BDTX-1535 and mTOR inhibitor, Temsirolimus. #AACR2025

Fantastic session on Hippo signaling in cancer at the AACR annual meeting. Exciting talks from Georg Halder, Kun-Liang Guan and William Hahn. The talk on the paradoxical data from YAP knockouts vs TEAD inhibitors was very insightful. #AACR2025

Susan Histed presenting first of five posters being presented at the AACR Annual Meeting from @ivycenter.bsky.social Her work focuses on preclinical drug combination studies in glioma models. #AACR2025

AACR takes great pride in bringing together people with diverse expertise to accelerate progress across the entire spectrum of cancer research. AACR President Patricia LoRusso addresses the #AACR25 Opening Ceremony.

Dr Larry Salzman, a physician and cancer survivor emphasized the importance of accessible clinical trials and cancer research for bringing new treatment options for cancer patients upon receiving the Distinguished Public Service award. #AACR2025

.@YoshieUmemura from @IvyBrainTumCtr presenting our PK/PD data from Phase 0/1 trial of AZD1390 which provides support for a phase 2/3 trial. #sno2024

After 6 years of being involved in early phase clinical trials, I was honored to present data from our Phase 0/2 study exploring CDK4/6i +ERKi in rGBM patients. Grateful to the collaborative team, patients and their families #SNO2024

Dr. An-Chi Tien from Ivy Center will be presenting compelling results from our Phase 0/1 study of BDTX-1535 in recurrent GBM patients with EGFR alterations at #SNO2024. 📍 Stop by the Poster Session in Hall B3, or explore our research at loom.ly/ciiEqXY 🧠

Meet Ivy Brain Tumor Center At The SNO Meeting 2024

Ivy Brain Tumor Center clinicians, scientists and researchers will participate at the Society for Neuro-Oncology (SNO) Meeting November 21-24 2024 in Houston TX.

loom.ly

Great to hear Douglas Hanahan give the Keynote talk at #SNO2024. Remembering the time in 2020 when we did some of these drug testing in GBM PDX models at Ivy Center.

Right on time to discuss at #SNO2024: Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma. www.nature.com/articles/s41...

Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma - Nature

The prodrug gliocidin effectively kills glioblastoma cells by targeting de novo purine synthesis, improving survival in mouse models.

nature.com